Genus plc
United Kingdom · GB0002074580 · reports in GBP · Europe
Four figures
From the annual report for the year to Jun 30, 2026. Each line says what it is based on.
- Revenue growth
- Revenue −2.2% in the year to Jun 30, 2026, on the year before.
- Return on equity
- It earned 37% on its shareholders' equity in the year to Jun 30, 2026.
- Equity and assets
- Equity is 75% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Jun 30, 2026, consolidated, in GBP.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 | |
|---|---|---|---|---|
| Revenue | £690M | £669M | £673M | £658M |
| Operating profit | £41M | £6M | £42M | £87M |
| Net profit to shareholders | £33M | £8M | £19M | £285M |
| Earnings per share | £0.51 | £0.12 | £0.29 | £4.32 |
| Cash from operations | −£31M | £30M | £67M | £74M |
| Capital spending | £26M | £15M | £13M | £13M |
| Cash | £36M | £43M | £48M | £44M |
| Total assets | £1.0B | £988M | £899M | £1.0B |
| Equity | £567M | £514M | £476M | £767M |
What they do
In the company's own words, from the annual report.
We produce elite animal genetics and sell them to farmers, along with services that help them to maximise the value of those genetics. Our customers access our genetics by buying live animals, semen or embryos, to use in their own breeding programmes.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.